1. Metabolic Enzyme/Protease Anti-infection Apoptosis Immunology/Inflammation NF-κB
  2. Tyrosinase Fungal SARS-CoV Apoptosis Reactive Oxygen Species (ROS)
  3. Retusin

Retusin  (Synonyms: Quercetin-​3,​3',​4',​7-​tetramethylether)

製品番号: HY-N6829 純度: 99.30%
COA 取扱説明書 Technical Support

Retusin (Quercetin-3,3',4',7-tetramethylether) is a tyrosinase inhibitor, with IC50 values of 50.9 μM and 51.8 μM against mushroom and intracellular tyrosinase, respectively. Retusin also acts as a free radical scavenger, melanogenesis inhibitor, anti-apoptosis agent, neuroprotective agent, antiemetic, antifungal agent, and antiviral agent. Retusin scavenges ABTS•+ and DPPH• free radicals. Retusin can be used in studies related to hyperpigmentation, vomiting, Aspergillus niger infection, and COVID-19 infection.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Retusin

Retusin 構造式

CAS 番号 : 1245-15-4

容量 価格(税別) 在庫状況 数量
1 mg $100 在庫あり
5 mg $225 在庫あり
10 mg $385 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

Other Forms of Retusin:

Top Publications Citing Use of Products
  • 生物活性

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー

製品説明

Retusin (Quercetin-3,3',4',7-tetramethylether) is a tyrosinase inhibitor, with IC50 values of 50.9 μM and 51.8 μM against mushroom and intracellular tyrosinase, respectively. Retusin also acts as a free radical scavenger, melanogenesis inhibitor, anti-apoptosis agent, neuroprotective agent, antiemetic, antifungal agent, and antiviral agent. Retusin scavenges ABTS•+ and DPPH• free radicals. Retusin can be used in studies related to hyperpigmentation, vomiting, Aspergillus niger infection, and COVID-19 infection[1][2][3][4][5].

Cellular Effect
Cell Line Type Value Description References
2008 IC50
>100 μM
Compound: 3, Pque
Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
2008 IC50
50 μM
Compound: 17
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
[PMID: 21354800]
A2780 ADR IC50
12 μM
Compound: 17
Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay
Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay
[PMID: 21354800]
A-375 IC50
69.72 μM
Compound: 3, Pque
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A-431 IC50
57.54 μM
Compound: 3, Pque
Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A-431 IC50
82.25 μM
Compound: 3, Pque
Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A549 IC50
>50 μM
Compound: 7a
Anticancer activity against human A549 cells by HTS assay
Anticancer activity against human A549 cells by HTS assay
[PMID: 25139569]
BXPC-3 IC50
>100 μM
Compound: 3, Pque
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
C13 IC50
>100 μM
Compound: 3, Pque
Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
Calu-1 IC50
6.53 μM
Compound: 7a
Anticancer activity against human Calu1 cells by HTS assay
Anticancer activity against human Calu1 cells by HTS assay
[PMID: 25139569]
HCT-15 IC50
68.11 μM
Compound: 3, Pque
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
HEK293 IC50
141.87 μM
Compound: 3, Pque
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
HeLa IC50
46.37 μM
Compound: 7a
Anticancer activity against human HeLa cells by HTS assay
Anticancer activity against human HeLa cells by HTS assay
[PMID: 25139569]
HL-60 IC50
28 μM
Compound: 19
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
[PMID: 25014747]
HOP-62 IC50
>50 μM
Compound: 7a
Anticancer activity against human HOP62 cells by HTS assay
Anticancer activity against human HOP62 cells by HTS assay
[PMID: 25139569]
KB ED50
>25 μg/mL
Compound: retusin
Cytotoxicity against human KB cells after 72 hrs
Cytotoxicity against human KB cells after 72 hrs
[PMID: 1955888]
KB ED50
41 μg/mL
Compound: NSC-61837
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
[PMID: 469554]
L929 IC50
>100 μM
Compound: 9, 3,7,3',4'-tetra-O-methylated quercetin
Cytotoxicity against mouse L929 cells after 5 days by MTS assay
Cytotoxicity against mouse L929 cells after 5 days by MTS assay
[PMID: 22743241]
LOX IMVI IC50
0.39 μM
Compound: 7a
Anticancer activity against human LOXIMVI cells by HTS assay
Anticancer activity against human LOXIMVI cells by HTS assay
[PMID: 25139569]
M14 IC50
0.38 μM
Compound: 7a
Anticancer activity against human M14 cells by HTS assay
Anticancer activity against human M14 cells by HTS assay
[PMID: 25139569]
MCF7 IC50
>100 μM
Compound: 3, Pque
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
MCF7 IC50
0.9 μM
Compound: 17
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
[PMID: 21354800]
MDCK IC50
0.39 μM
Compound: 17
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
[PMID: 21354800]
MDCK IC50
16 μM
Compound: 17
Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry
Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry
[PMID: 21354800]
MDCK-II IC50
0.54 μM
Compound: 12
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay
[PMID: 23851114]
MDCK-II IC50
0.57 μM
Compound: 12
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry
[PMID: 23851114]
NCI/ADR-RES IC50
>100 μM
Compound: 3, Pque
Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
NCI-H1299 IC50
10.46 μM
Compound: 7a
Anticancer activity against human H1299 cells by HTS assay
Anticancer activity against human H1299 cells by HTS assay
[PMID: 25139569]
NCI-H157 IC50
>50 μM
Compound: 7a
Anticancer activity against human NCI-H157 cells by HTS assay
Anticancer activity against human NCI-H157 cells by HTS assay
[PMID: 25139569]
NCI-H1792 IC50
>50 μM
Compound: 7a
Anticancer activity against human NCI-H1792 cells by HTS assay
Anticancer activity against human NCI-H1792 cells by HTS assay
[PMID: 25139569]
NCI-H1944 IC50
>50 μM
Compound: 7a
Anticancer activity against human NCI-H1944 cells by HTS assay
Anticancer activity against human NCI-H1944 cells by HTS assay
[PMID: 25139569]
NCI-H460 IC50
>50 μM
Compound: 7a
Anticancer activity against human H460 cells by HTS assay
Anticancer activity against human H460 cells by HTS assay
[PMID: 25139569]
NCI-H522 IC50
>50 μM
Compound: 7a
Anticancer activity against human NCI-H522 cells by HTS assay
Anticancer activity against human NCI-H522 cells by HTS assay
[PMID: 25139569]
Neutrophil IC50
1.43 μg/mL
Compound: 10
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced superoxide anion generation
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced superoxide anion generation
[PMID: 18163582]
Neutrophil IC50
1.69 μg/mL
Compound: 10
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release
[PMID: 18163582]
体外実験

Retusin (20-80 μM; 48 h) reduces the viability of B16F10 mouse melanoma cells to 35.7% (40 μM) and 3.2% (80 μM) of that in the control group, while decreasing the viability of HaCaT human keratinocytes to 99.2% (20 μM) and 40.4% (40 μM) of the control level[1].
Retusin (10 μM; 48 h) reduces α-MSH-induced melanin production to 56.6% of that in the control group and decreases cellular tyrosinase activity to 49.9% of the control level in B16F10 mouse melanoma cells[1].
Retusin (0.1-10 μM; 24 h) considerably increases the percentage of live Neuro-2a cells and decreases the number of early apoptotic cells[2].
Retusin (24-48 h) potently inhibits Aspergillus niger with an MIC of 100 μg/mL; at a concentration of 100 μg/mL, this compound shows no activity against the tested bacteria, other fungi or yeasts[4].
Retusin (0.01-10 μM; 24 h) potently inhibits SARS-CoV-2 replication in Vero E6 cells, with an EC50 of 0.4 μM[5].
Retusin (0.01-10 μM; 48 h) potently inhibits SARS-CoV-2 replication in Calu-3 cells, with an EC50 of 0.6 μM[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: B16F10 murine melanoma cells, HaCaT human keratinocytes
Concentration: 40 μM (B16F10 cells); 80 μM (B16F10 cells); 20 μM (HaCaT cells); 40 μM (HaCaT cells)
Incubation Time: 48 h
Result: Reduced B16F10 cell viability to 35.7% of control at 40 μM and 3.2% of control at 80 μM.
Reduced HaCaT cell viability to 99.2% of control at 20 μM and 40.4% of control at 40 μM.

Apoptosis Analysis[2]

Cell Line: Neuro-2a cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Significantly alleviated the apoptosis damage of Neuro-2a cells induced by 6-OHDA (HY-B1081).
体内実験

Retusin (10-50 mg/kg; i.p.; single dose) dose-dependently inhibits Copper sulfate (HY-Y1878)-induced emesis in young chicks, with a maximum 45.6% inhibition at 50 mg/kg[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Young male chicks (4 days of age, 25-35 g)[3]
Dosage: 10 mg/kg; 20 mg/kg; 50 mg/kg
Administration: i.p.; single dose
Result: Reduced the mean number of retches to 49.0 (27.4% inhibition vs control).
Reduced the mean number of retches to 48.0 (28.9% inhibition vs control).
Reduced the mean number of retches to 36.7 (45.6% inhibition vs control).
分子量

358.34

分子式

C19H18O7

CAS 番号
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1C(OC)=C(C2=CC=C(OC)C(OC)=C2)OC3=CC(OC)=CC(O)=C13

Structure Classification
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度
体外: 

DMSO : 25 mg/mL (69.77 mM; ultrasonic and warming and heat to 70°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7906 mL 13.9532 mL 27.9065 mL
5 mM 0.5581 mL 2.7906 mL 5.5813 mL
10 mM 0.2791 mL 1.3953 mL 2.7906 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます:C1V1 = C2V2

濃度 (開始)

C1

×
体積 (開始)

V1

=
濃度 (終了)

C2

×
体積 (終了)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
純度とドキュメンテーション

純度: 99.30%

参考文献

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.7906 mL 13.9532 mL 27.9065 mL 69.7661 mL
5 mM 0.5581 mL 2.7906 mL 5.5813 mL 13.9532 mL
10 mM 0.2791 mL 1.3953 mL 2.7906 mL 6.9766 mL
15 mM 0.1860 mL 0.9302 mL 1.8604 mL 4.6511 mL
20 mM 0.1395 mL 0.6977 mL 1.3953 mL 3.4883 mL
25 mM 0.1116 mL 0.5581 mL 1.1163 mL 2.7906 mL
30 mM 0.0930 mL 0.4651 mL 0.9302 mL 2.3255 mL
40 mM 0.0698 mL 0.3488 mL 0.6977 mL 1.7442 mL
50 mM 0.0558 mL 0.2791 mL 0.5581 mL 1.3953 mL
60 mM 0.0465 mL 0.2326 mL 0.4651 mL 1.1628 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量   濃度   体積   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

一般には略語で表示されます:C1V1 = C2V2

濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

最近チェックした製品:

オンラインお問い合わせ

Your information is safe with us. * Required Fields.

製品名

 

カスタマ需要量 *

お名前 *

 

タイトル

メールアドレス *

 

電話番号 *

デパートメント

 

組纖名 *

市区町村

都道府県

国或いは地域 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
Retusin
製品番号:
HY-N6829
数量:
MCE 日本正規代理店: